<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401880</url>
  </required_header>
  <id_info>
    <org_study_id>EMLIN-001</org_study_id>
    <nct_id>NCT02401880</nct_id>
  </id_info>
  <brief_title>Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology</brief_title>
  <official_title>Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this exploratory mechanistic study is to investigate the effects of
      Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients.

      This study aims to evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to
      placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell
      function, as well as several markers of metabolic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be performed as a multi-center study which includes 2 centres. 44 subjects
      with T2DM are to be included according to the defined in- and exclusion criteria.

      Subjects has to be on a stable metformin therapy and will receive in a first step
      empagliflozin for 30 days. Both therapies (metformin and empagliflozin) will be continued for
      another 30 days and subjects will be randomized to receive in addition Linagliptin or Placebo
      for 30 days.

      Subjects will come for two inhouse periods to their corresponding study center and will
      undergo an hyperglycaemic clamp test as well as a Meal test in each of the periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Change in glucagon release (AUC0-180 min) during Liquid Meal Test (LMT) from V3 to V4 between the two treatment groups (Linagliptin vs. placebo)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Change in glucagon release (AUC0-180 min) during LMT from V2 to V3 during treatment with Empagliflozin (V2 vs. V3)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Empagliflozin plus Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Empagliflozin 25mg will be adminstered for 30 days in T2DM patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>22 subjects will receive Linagliptin for 30 days</description>
    <arm_group_label>Empagliflozin plus Linagliptin</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>22 subjects will receive Placebo for 30 days</description>
    <arm_group_label>Empagliflozin plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>44 subjects will receive Empagliflozin for 60 days</description>
    <arm_group_label>Empagliflozin plus Linagliptin</arm_group_label>
    <arm_group_label>Empagliflozin plus Placebo</arm_group_label>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject with diabetes mellitus type 2

          2. Diabetes mellitus type 2 on stable treatment with metformin (daily dose at least 1000
             mg) for at least 6 months

          3. HbA1c 7.0%-9.9%, both inclusive

          4. Diabetes duration of at least 24 months)

        Exclusion Criteria:

          1. History of diabetes mellitus type 1

          2. GFR (as calculated by the Cockcroft-Gault equation) &lt; 60 ml/min at Screening

          3. Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure
             above 95 mmHg at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

